Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 102 clinical trials
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose

  • 252 views
  • 04 Jan, 2022
  • 79 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does …

gilbert's syndrome
advanced cancer
lymphoma
ct scan
neutrophil count
  • 22 views
  • 17 Jan, 2022
  • 96 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

dabrafenib
targeted therapy
dasatinib
brain tumor
primary brain tumors
  • 6426 views
  • 19 Jan, 2022
  • 1030 locations
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute

  • 0 views
  • 02 Jan, 2022
  • 54 locations
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

refractory peripheral t-cell lymphoma
peripheral t-cell lymphoma
prolymphocytic leukemia
fungal infection
t-cell lymphoma
  • 0 views
  • 26 Jan, 2022
  • 15 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and

measurable disease
dexamethasone
lymphoma
multiple myeloma
primary cancer
  • 11 views
  • 21 Jan, 2022
  • 12 locations
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and

lymphoma
multiple myeloma
  • 0 views
  • 22 Jan, 2022
  • 5 locations
FT576 in Subjects With Multiple Myeloma

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation

measurable disease
fludarabine
  • 0 views
  • 22 Jan, 2022
  • 2 locations
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

of an antibody called anti-CD138. This antibody floats around in the blood and can detect and stick to cancer cells called multiple myeloma cells because they have a substance on the outside of the

toxic substances
melphalan
activated t cells
immunosuppressants
cancer
  • 25 views
  • 29 Dec, 2021
  • 1 location
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After …

proteasome inhibitor
rituximab
immunomodulatory imide drug
immunotherapeutic agent
lymphoma
  • 5 views
  • 02 Jan, 2022
  • 35 locations